Compile Data Set for Download or QSAR
Report error Found 206 Enz. Inhib. hit(s) with all data for entry = 1564
TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615117(US20230271945, Compound 36)
Affinity DataIC50: 600nMAssay Description:Briefly, the AlamarBlue active compound, the resazurin, a blue, water soluble, non-toxic and cell permeable molecule, which can be followed by absorb...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615117(US20230271945, Compound 36)
Affinity DataIC50: 600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615116(US20230271945, Compound 35)
Affinity DataIC50: 600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615115(US20230271945, Compound 34)
Affinity DataIC50: 600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615119(US20230271945, Compound 38 | US20230271945, Compou...)
Affinity DataIC50: 600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615118(US20230271945, Compound 37)
Affinity DataIC50: 600nMAssay Description:Briefly, the AlamarBlue active compound, the resazurin, a blue, water soluble, non-toxic and cell permeable molecule, which can be followed by absorb...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615118(US20230271945, Compound 37)
Affinity DataIC50: 600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM50547877(CHEMBL4795347 | US20230271945, Compound 42)
Affinity DataIC50: 600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615121(US20230271945, Compound 40)
Affinity DataIC50: 600nMAssay Description:Briefly, the AlamarBlue active compound, the resazurin, a blue, water soluble, non-toxic and cell permeable molecule, which can be followed by absorb...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615121(US20230271945, Compound 40)
Affinity DataIC50: 600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615125(3-(5-chloro-2-phenyl-1H-indol-3-yl)-N-[(3S,4R)-4-h...)
Affinity DataIC50: 600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615124(3-[2-(4-bromophenyl)-5-methyl-1H-indol-3-yl]-N-[(3...)
Affinity DataIC50: 600nMAssay Description:Briefly, the AlamarBlue active compound, the resazurin, a blue, water soluble, non-toxic and cell permeable molecule, which can be followed by absorb...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615124(3-[2-(4-bromophenyl)-5-methyl-1H-indol-3-yl]-N-[(3...)
Affinity DataIC50: 600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM50547877(CHEMBL4795347 | US20230271945, Compound 42)
Affinity DataIC50: 600nMAssay Description:Briefly, the AlamarBlue active compound, the resazurin, a blue, water soluble, non-toxic and cell permeable molecule, which can be followed by absorb...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615107(US20230271945, Compound 26)
Affinity DataIC50: 600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615106(US20230271945, Compound 25)
Affinity DataIC50: 600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615105(US20230271945, Compound 24)
Affinity DataIC50: 600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615104(US20230271945, Compound 23)
Affinity DataIC50: 600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615108(US20230271945, Compound 27)
Affinity DataIC50: 600nMAssay Description:Briefly, the AlamarBlue active compound, the resazurin, a blue, water soluble, non-toxic and cell permeable molecule, which can be followed by absorb...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615108(US20230271945, Compound 27)
Affinity DataIC50: 600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615107(US20230271945, Compound 26)
Affinity DataIC50: 600nMAssay Description:Briefly, the AlamarBlue active compound, the resazurin, a blue, water soluble, non-toxic and cell permeable molecule, which can be followed by absorb...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615111(US20230271945, Compound 30)
Affinity DataIC50: 600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615110(US20230271945, Compound 29)
Affinity DataIC50: 600nMAssay Description:Briefly, the AlamarBlue active compound, the resazurin, a blue, water soluble, non-toxic and cell permeable molecule, which can be followed by absorb...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615110(US20230271945, Compound 29)
Affinity DataIC50: 600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615113(US20230271945, Compound 32)
Affinity DataIC50: 600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615111(US20230271945, Compound 30)
Affinity DataIC50: 600nMAssay Description:Briefly, the AlamarBlue active compound, the resazurin, a blue, water soluble, non-toxic and cell permeable molecule, which can be followed by absorb...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615139(US20230271945, Compound 58)
Affinity DataIC50: 600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615140(US20230271945, Compound 59)
Affinity DataIC50: 600nMAssay Description:Briefly, the AlamarBlue active compound, the resazurin, a blue, water soluble, non-toxic and cell permeable molecule, which can be followed by absorb...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615140(US20230271945, Compound 59)
Affinity DataIC50: 600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615139(US20230271945, Compound 58)
Affinity DataIC50: 600nMAssay Description:Briefly, the AlamarBlue active compound, the resazurin, a blue, water soluble, non-toxic and cell permeable molecule, which can be followed by absorb...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615144(US20230271945, Compound 63)
Affinity DataIC50: 600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615143(N-[(3S,4R)-4-hydroxy-2-oxo-pyrrolidin-3-yl]-3-(2-p...)
Affinity DataIC50: 600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM50547878(CHEMBL4752052 | US20230271945, Compound 61)
Affinity DataIC50: 600nMAssay Description:Briefly, the AlamarBlue active compound, the resazurin, a blue, water soluble, non-toxic and cell permeable molecule, which can be followed by absorb...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM50547878(CHEMBL4752052 | US20230271945, Compound 61)
Affinity DataIC50: 600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615127(US20230271945, Compound 46)
Affinity DataIC50: 600nMAssay Description:Briefly, the AlamarBlue active compound, the resazurin, a blue, water soluble, non-toxic and cell permeable molecule, which can be followed by absorb...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615127(US20230271945, Compound 46)
Affinity DataIC50: 600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615126(3-[5-chloro-2-(4-fluorophenyl)-1H-indol-3-yl]-N-[(...)
Affinity DataIC50: 600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615125(3-(5-chloro-2-phenyl-1H-indol-3-yl)-N-[(3S,4R)-4-h...)
Affinity DataIC50: 600nMAssay Description:Briefly, the AlamarBlue active compound, the resazurin, a blue, water soluble, non-toxic and cell permeable molecule, which can be followed by absorb...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615129(US20230271945, Compound 48)
Affinity DataIC50: 600nMAssay Description:Briefly, the AlamarBlue active compound, the resazurin, a blue, water soluble, non-toxic and cell permeable molecule, which can be followed by absorb...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615129(US20230271945, Compound 48)
Affinity DataIC50: 600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615128(US20230271945, Compound 47)
Affinity DataIC50: 600nMAssay Description:Briefly, the AlamarBlue active compound, the resazurin, a blue, water soluble, non-toxic and cell permeable molecule, which can be followed by absorb...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615128(US20230271945, Compound 47)
Affinity DataIC50: 600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615133(US20230271945, Compound 52)
Affinity DataIC50: 600nMAssay Description:Briefly, the AlamarBlue active compound, the resazurin, a blue, water soluble, non-toxic and cell permeable molecule, which can be followed by absorb...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615133(US20230271945, Compound 52)
Affinity DataIC50: 600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615132(US20230271945, Compound 51)
Affinity DataIC50: 600nMAssay Description:Briefly, the AlamarBlue active compound, the resazurin, a blue, water soluble, non-toxic and cell permeable molecule, which can be followed by absorb...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615132(US20230271945, Compound 51)
Affinity DataIC50: 600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615157(US20230271945, Compound 76)
Affinity DataIC50: 600nMAssay Description:Briefly, the AlamarBlue active compound, the resazurin, a blue, water soluble, non-toxic and cell permeable molecule, which can be followed by absorb...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615157(US20230271945, Compound 76)
Affinity DataIC50: 600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615161(US20230271945, Compound 80)
Affinity DataIC50: 600nMAssay Description:Briefly, the AlamarBlue active compound, the resazurin, a blue, water soluble, non-toxic and cell permeable molecule, which can be followed by absorb...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargetApolipoprotein L1(Human)
Vertex Pharmaceuticals

US Patent
LigandPNGBDBM615161(US20230271945, Compound 80)
Affinity DataIC50: 600nMAssay Description:Apolipoprotein L1 (APOL1) proteins form potassium-permeable cation pores in the plasma membrane. APOL1 risk variants (G1 and G2) induce greater potas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

Displayed 1 to 50 (of 206 total ) | Next | Last >>
Jump to: